Novel investigational drugs for gastric cancer

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer. J Clin 2008;58:71-96
   Google Scholar
• Blot WJ, Mclaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8
   PubMed Web of Science ®Google Scholar
• Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005;23:1237-44
   PubMed Web of Science ®Google Scholar
• Allal AS, Zwahlen D, Brundler MA, et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 2005;63:1286-9
   PubMed Web of Science ®Google Scholar
• MacDonald JS. Role of post-operative chemoradiation in resected gastric cancer. J Surg Oncol 2005;90:166-70
   PubMed Web of Science ®Google Scholar
• Kim S, Lim do H, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-85
   PubMed Web of Science ®Google Scholar
• Allum W, Cunningham D, Weeden S, et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomized, controlled trial (the MAGIC trial, ISRCTN 93793971) [abstract 998]. Proc ASCO 2008;22:249a
   Google Scholar
• Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol 2005;31:453-60
   PubMed Web of Science ®Google Scholar
• Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) pls supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Kornek G, Zeh B, et al. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer a randomized trial. Proceedings of the Second International Conference on Biology, Prevention and treatment of GI Malignancy. Köln, Germany, 1995;68
   Google Scholar
• Grimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8
   Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer). J Clin Oncol 1997;15:261-7
   PubMed Web of Science ®Google Scholar
• Van Custem E, Moiseyenko M, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006;24:4991-7
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin in advanced esophagogastric cancer. New Engl J Med 2008;358:36-46
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007;31:1458-68
   PubMed Web of Science ®Google Scholar
• Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008;15:69-79
   PubMed Web of Science ®Google Scholar
• Tokunaga A, Onda M, Okuda T, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995;75:1418-25
   PubMed Web of Science ®Google Scholar
• Takehana T, Kunitomo K, Suzuki S, et al. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 2003;1:438-45
   PubMed Web of Science ®Google Scholar
• Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann of Oncol 2007;18:510-17
   PubMed Web of Science ®Google Scholar
• Lordick F, Lorenzen S, Hegewisch-becker S, et al. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group [abstract 4526]. Gastrointestinal (Noncolorectal) Cancer, 2007 ASCO Annual Meeting
   Google Scholar
• Wöll E, Kühr T, Eisterer W. Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT). Anticancer Res 2008;28:2901-5
   PubMed Web of Science ®Google Scholar
• Wöll E, Greil W, Eisterer M, et al. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. First results of a multicenter phase II trial (GTM Gastric-2) [abstract 15587]. Gastrointestinal (Noncolorectal) Cancer, 2008 ASCO Annual Meeting, 30 May – 3 June, Chicago, IL, USA
   Google Scholar
• Moehler MH, Trarbach T, Seufferlein T, et al. Cetuximab with irinotecan/Na-Fa/5-FU as first-line treatment in advanced gastric cancer: preliminary results of a nonrandomised multi-centre AIO phase II study [abstract 102]. 2008 Gastrointestinal Cancers Symposium, ASCO 2008, 25 – 27 January, Orlando, FL, USA
   Google Scholar
• Zhang X, Xu J, Shen L, et al. A phase II study of cetuximab (Cetuximab) with cisplatin and capecitabine (Xeloda) as 1st line treatment in advanced gastric cancer [abstract 15663]. Gastrointestinal (Noncolorectal) Cancer, 2008 ASCO Annual Meeting, 30 May – 3 June, Chicago, IL, USA
   Google Scholar
• Pinto C, Di FABIO, F BARONE, et al. Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study) [abstract 4575]. Gastrointestinal (Noncolorectal) Cancer, 2008 ASCO Annual Meeting, 30 May – 3 June, Chicago, IL, USA
   Google Scholar
• Tebbutt NC, Sourjina T, Strickland AH, et al. “ ATTAX2: docetaxel plus cetuximab as second line treatment for docetaxel-refractory oesophago-gastric cancer. Final results of a multicentre phase II trial by the AGITG [abstract 15554]. Gastrointestinal (Noncolorectal) Cancer, 2008 ASCO Annual Meeting, 30 May – 3 June, Chicago, IL, USA
   Google Scholar
• Rao S, Starling N, Cunningham D. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008;99:868-74
   PubMed Web of Science ®Google Scholar
• Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD 1839) in pretreated patients with metastatic gastric cancer [abstract 1036]. Proc Am Soc Clin Oncol 2003;22:258
   Google Scholar
• Adelstein DJ, Rybicki LA, Carrol M, et al. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesphageal junction (GEJ) cancer. Proc Gastrointest Am Soc Clin Oncol Symp 2005;85:A5
   Google Scholar
• Kaptain S, Tan LK, Chen B, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. JCO 2006;24:4309-316
   PubMed Web of Science ®Google Scholar
• Kaptain S, Tan LK, Chen B. Her–2/neu and breast cancer. Diagn Mol Pathol 2001;10:139-52
   PubMed Web of Science ®Google Scholar
• Yano T, Ochiai A, Doi T, et al. Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit [abstract 4053]. J Clin Oncol 2004;22:14S
   Google Scholar
• Lordick F, Bang YJ, Kang YK, et al. HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer [abstract 3541]. Eur J Cancer 2007;5:271
   Web of Science ®Google Scholar
• Gravalos C, Márquez A, García-carbonero R, et al. Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study [abstract 89]. Gastrointestinal Cancers Symposium, 19 – 21 January 2007, Orlando, FL, USA;130
   Google Scholar
• Kang Y, Bang Y, Lordick F, et al. Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity (abstract 11). Gastrointestinal Cancers Symposium. 2008;75
   Google Scholar
• Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-27
   PubMed Web of Science ®Google Scholar
• Tateishi M, Toda T, Minamisono Y, et al. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. Surg Oncol 1992;49:209-12
   Web of Science ®Google Scholar
• Sasano H, Date F, Imatani A, et al. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993;24:584-9
   PubMed Web of Science ®Google Scholar
• Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993;72:3179-84
   PubMed Web of Science ®Google Scholar
• Mizutani T, Onda M, Tokunaga A, et al. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993;72:2083-8
   PubMed Web of Science ®Google Scholar
• Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 1999;85:1894-902
   PubMed Web of Science ®Google Scholar
• Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-9
   PubMed Web of Science ®Google Scholar
• Matsui Y, Inomata M, Tojigamori M, et al. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005;27:681-5
   PubMed Web of Science ®Google Scholar
• Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007;59:795-805
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008;32:89-95
   PubMed Web of Science ®Google Scholar
• Cortés-Funes H, Rivera F, Alés I, et al. Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/amplification [abstract 4613]. J Clin Oncol 2007;15:18S
   Google Scholar
• Nicholas G, Cripps C, Au H-P, et al. Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2 [abstract 1105]. ESMO 2006;17(Suppl 9):316
   Google Scholar
• Rech J, Arnold D, Folprecht G, et al. A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer [abstract 1096]. ESMO 2006;17(Suppl 9):314
   Google Scholar
• Kim JW, Kim HP, Im SA, et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008;272(2):296-306
   PubMed Web of Science ®Google Scholar
• Iqbal S, Goldman B, Lenz HJ, et al. S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer [abstract 4621]. Gastrointestinal (Noncolorectal) Cancer, 2007 ASCO Annual Meeting, 1 – 5 June, Chicago, IL, USA
   Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nature Med 2003;9:669-76
   PubMed Web of Science ®Google Scholar
• Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179-213
   PubMed Web of Science ®Google Scholar
• Maeda K, Chung YS, Ogawa S, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77;858-63
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000;153:7-12
   PubMed Web of Science ®Google Scholar
• Sandler AB, Gray R, Brahmer A, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial – E4599. N Engl J Med 2006;355:2542-50. Erratum in: N Engl J Med 2007;356:318
   PubMed Web of Science ®Google Scholar
• Miller KD, Wang M, Gralow J, et al. E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Saltz Clarke S, Diaz-Rubio E. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26;2013-19
   Google Scholar
• Kanai T, Konno H, Tanaka T, et al. Anti-tumor and anti-metastatic effects of human vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998;77:185-90
   Web of Science ®Google Scholar
• Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan and bevacizumab-based therapy. J Clin Oncol 2005;23:2574-6
   PubMed Web of Science ®Google Scholar
• Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-6
   PubMed Web of Science ®Google Scholar
• El-rayes BF, Hammad N, Philip PA, et al. A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junct (GEJ) cancer [abstract 15608]. Gastrointestinal (Noncolorectal) Cancer, 2008 ASCO Annual Meeting, 30 May – 3 June, Chicago, IL, USA
   Google Scholar
• Sun W, Powell ME, et al. A phase II study: combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203) [abstract 4535]. Gastrointestinal (Noncolorectal) Cancer, 2008 ASCO Annual Meeting, 30 May – 3 June, Chicago, IL, USA
   Google Scholar
• Bang Y, Kang Y, Kang W, et al. Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study [abstract 4603]. Gastrointestinal (Noncolorectal) Cancer, 2007 ASCO Annual Meeting, 1 – 5 June, Chicago, IL, USA
   Google Scholar
• Davies B, Waxman J, Wasan H, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993;53:5365-9
   PubMed Web of Science ®Google Scholar
• Montgomery AM, Mueller BM, Reisfeld RA, et al. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994;54:5467-73
   PubMed Web of Science ®Google Scholar
• Monig SP, Baldus SE, Hennecken JK, et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001;39:597-602
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic [Review]. Semin Cancer Biol 1996;7:147-54
   PubMed Web of Science ®Google Scholar
• Kimata M, Otani Y, Kubota T, et al. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Jpn J Cancer Res 2002;93:834-1
   PubMedGoogle Scholar
• Watson SA, Morris TM, Collins HM, et al. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br J Cancer 1999;81:19-23
   PubMed Web of Science ®Google Scholar
• Tierney GM, Griffin NR, Stuart RC, et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999;35:563-8
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Hallissey MT, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002;86:1864-70
   PubMed Web of Science ®Google Scholar
• Hashimoto I, Koizumi K, Tatematsu M, et al. Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer 2008;44:1022-9
   PubMed Web of Science ®Google Scholar
• Muro K, Boku N, Yamada Y, et al. Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): Preliminary results [abstract 4541]. Gastrointestinal (Noncolorectal) Cancer, 2008 ASCO Annual Meeting, 30 May – 3 June, Chicago, IL, USA
   Google Scholar
• Enzinger PC, Ryan DP, Regan EM, et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer [abstract 97]. 2008 Gastrointestinal Cancers Symposium, ASCO 2008, 25 – 27 January, Orlando, FL, USA
   Google Scholar
• Cohenuram MK, Lacy J. FOLFOX6 and bevacizumab (FOLFOX6/B) for metastatic esophageal (E), gastroesophageal (GE), and gastric (G) adenocarcinoma: a single institution's initial clinical experience [abstract 74]. 2008 Gastrointestinal Cancers Symposium, ASCO 2008, 25 – 27 January, Orlando, FL, USA
   Google Scholar
• Hammad N, Philip PA, Shields AF, et al. A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer [abstract 30]. 2008 Gastrointestinal Cancers Symposium, ASCO 2008, 25 – 27 January, Orlando, FL, USA
   Google Scholar
• Jhawer MP, Ilson D, Robinson E, et al. Interim results of a phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma [abstract 109]. 2008 Gastrointestinal Cancers Symposium, ASCO 2008, 25 – 27 January, Orlando, FL, USA
   Google Scholar